China Resources Double-Crane Pharmaceutical (Jinan) Co., Ltd.

Primary research objective: In accordance with relevant bioequivalence testing regulations, domenorrhea tablets (trade name: Ulexi, strength: 2mg), manufactured by FUJI YAKUHIN CO., LTD., a licensee, were selected as the reference formulation. A preliminary human bioequivalence study was conducted on domenorrhea tablets (strength: 2mg), manufactured by and supplied by CR Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd., under fasting and postprandial administration. The pharmacokinetic characteristics of the test and reference formulations after fasting and postprandial administration were estimated to provide a reference for the design of the formal trial. Secondary research objective: To observe the safety of oral administration of the test and reference formulations, domenorrhea tablets (strength: 2mg), to healthy participants.

Primary Objective: To compare the extent and rate of absorption of the test formulation, 75 mg polyprednisolone zinc orally disintegrating tablets (supplied by China Resources Double Crane Limin Pharmaceuticals (Jinan) Co., Ltd.), and the reference formulation, 75 mg polyprednisolone zinc orally disintegrating tablets (trade name: Promac® D) from Zeria Shinyaku Kogyo Co., Ltd., in healthy Chinese subjects under fasting and fed conditions, and to evaluate the bioequivalence of the two formulations. Secondary Objectives: 1) To evaluate the safety of the test formulation and the reference formulation in healthy Chinese subjects under fasting and fed conditions. 2) To evaluate the oral texture of the formulations in healthy Chinese subjects under fasting and fed conditions, and to provide evidence for the oral texture of polyprednisolone zinc orally disintegrating tablets.

Main purpose: To compare the differences in the degree and rate of absorption of aluminum magnesium aspirin tablets (II) (specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) provided by China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. and aluminum magnesium aspirin tablets (II) (trade name: BUFFERIN Combination Tab. A81; specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) certified by Lion Corporation in healthy Chinese population under fasting and postprandial administration conditions. Secondary objective: To evaluate the safety of BUFFERIN Combination Tab. A81 (Specification: Each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, and 11 mg aluminum glycolate) provided by China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. and BUFFERIN Combination Tab. A81 (Specification: Each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, and 11 mg aluminum glycolate) certified by Lion Corporation in healthy study participants under fasting and postprandial conditions.